Anticancer effect of PMEDAP - Monitoring of apoptosis

Anticancer Research

Volumn 20, Issue 2 A, 2000, Pages 1041-1047

  Bobková, Klára ^a,b   Otová, Berta ^a   Marinov, Iuri ^c   Mandys, Václav ^d,e   Panczak, Aleš ^a   Votruba, Ivan ^f   Holy, Antonín ^f  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Cytolab Sro   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Apoptosis; Bcl2; p53; PMEDAP; Rat; Spontaneous lymphoma

Indexed keywords

9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE DERIVATIVE; ANTINEOPLASTIC AGENT; BROXURIDINE; CD4 ANTIGEN; DNA FRAGMENT; PROTEIN BCL 2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL STRUCTURE; CHROMOSOME 11; CONTROLLED STUDY; IMMUNOPHENOTYPING; KARYOTYPE; NONHUMAN; PRIORITY JOURNAL; RAT; T CELL LYMPHOMA; TRISOMY; TUMOR VOLUME;

ADENINE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHROMOSOME MAPPING; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KARYOTYPING; LYMPHOMA, T-CELL; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; TRISOMY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034052289     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Klír P, Svoboda T, Přibylová M and Tachecí O: Spontaneous mononuclear cell leukemia in Sprague-Dawley rats, a possible model. Deutsch TierArztl Wschr 92: 21, 1984.
2. Otová B, Sladká M, Panczak A and Marinov I: Biological characteristics of spontaneous transplantable T-cell lymphomas in inbred Sprague-Dawley/Cub Rats. Transplant Proc 29: 1754-1755, 1997.
3. Sladká M and Otová B: Cytogenetic changes in Sprague-Dawley rat lymphomas in the course of in vivo passages. Folia Biol (Praha) 44: 143-150, 1998.
4. Otová B, Sladká M, Damoiseaux J, Panczak A, Mandys V, Francová K and Kudláčková M: Characterization of T-cell lymphomas in the Prague inbred Sprague-Dawley/Cub rat strain: A model of spontaneous hematological malignancy. Transplant Proc 31: 1618-1619, 1999.
5. Otová B, Zídek Z. Holý A, Votruba I, Sladká M, Marinov I and Lešková V: Antitumor activity of novel purine nucleotide analogs PMEA and PMEDAP. In Vivo 11: 163-168, 1997.
6. Halicka HD, Seiter K, Feldman EJ, Traganos F, Mittelman A, Ahmed T and Darzynkiewicz Z: Cell cycle specificity of apoptosis during treatment of leukemias. Apoptosis 2: 25-39, 1997.
7. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR and Sikorska M: Apoptotic death in epithelial cells; cleavage of DNA to 300 and/or 50 kb fragments prior or in the absence of internucleosomal fragmentation. EMBO 12: 3679-3684, 1993.
8. Arenas MJ and Wyllie AH: Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 32: 223-254, 1991.
9. Lane DP: p53, a guardian of the genome. Nature 358: 15-16, 1992.
10. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a Potential Mediator of p53 tumor suppression. Cell 75: 817-823, 1993.
11. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Dip 1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 75: 805-812, 1993.
12. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR and Theologides A: Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N. Engl J Med 307: 1231-1236, 1982.
13. Steube KG, Jadau A, Teepe D and Drexler HG: Expression of bcl-2 mRNA and protein in leukemia-lymphoma cell lines. Leukemia 9: 1841-1846, 1995.
14. Holý A, Votruba I, Merta A, Černý J, Veselý J, Vlach J, Šedivá K, Rosenherg I, Otmar M, Hřebabecký H, Trávníček M, Vonka V, Snoeck R and De Clercq E: Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res 13: 245-312, 1990.
15. De Clercq E: Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem Pharmacol 42: 963-972, 1991.
16. Naesens L, Balzarini J, Rosenberg I, Holý A and De Clercq E: 9-(2-Phosphonyl methoxyethyl)-2,6-diaminopurine (PMEDAP): A novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis 8: 1043-1047, 1989.
17. Naesens L, Balzarini J and De Clercq E: Single dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res 16: 53-64, 1991.
18. Naesens L, Neyts J, Balzarini J, Holý A, Rosenberg I and De Clercq E: Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. J Med Virol 39: 167-172, 1993.
19. Veselý J, Merta A, Votruba I, Holý A and Rosenberg I: The cytostatic effects and mechanism of action of antiviral acyclic adenine nucleotide analogues in L1210 mouse leukemic cells. Neoplasma 37: 105-110, 1990.
20. Otová B, Panczak A, Francová K, Mandys V, Marinov I., Kohoutová M, Sladká M. Kudláčková M, Votruba I and Holý A: Experimental therapy of T-cell lymphomas in inbred SD/cub rats. Cancer Det Prev 22: S 244, 1998.
21. Křen V, Otová B, Elleder D, Elleder M, Panczak A and Holý A: Prevention of acute graft-versus-host disease in rats using 9-[2-(phosphonomethoxy)ethyl]-adenine (PMEA). Folia Biol (Praha) 39: 78-86, 1993.
22. Otová B, Zídek Z, Holý A, Votruba I and Franková D: Immunomodulatory properties of 9-[2-(phosphonomethoxy)-ethyl] adenine (PMEA). Folia Biol (Praha) 40: 185-192, 1994.
23. Bílá V, Otová B, Jelinek R, Sladká M, Mejsnarová B, Holý A and Křen V: Antimitotic and teratogenic effects of acyclic nucleotide analogues 1-(S)-(3-hydroxy-2-phosphonomethoxypropyl)-cytosine (HPMPC) and 9-(2-phosphonomethoxyethyl)-adenine (PMEA). Folia Biol (Praha) 39: 150-161, 1993.
24. Stetina R, Votruba I, Holý A and Merta A: The effect of purine phosphonomethoxyalkyl derivatives on DNA synthesis in CHO Chinese hamster cells. Neoplasma 41: 61-66, 1994.
25. Otová B, Holý A, Votruba I. Sladká M, Bílá V, Mejsnarová B and Lešková V: Genotoxicity of Purine Acyclic Nucleotide Analogs. Folia Biol (Praha) 43: 225-229, 1997.
26. Kramata P, Votruba I, Otová B and Holý A: Different inhibitory potencies of acyclic phospho-no-methoxyalkyl nucleotide analogs toward DNA polymerases α, δ and ε. Mol Pharmacol 49: 1005-1011, 1996.
27. Franěk F, Holý A, Votruba I and Eckschlager T: Acyclic nucleotide analogues suppress growth and induce apoptosis in human leukemia cell lines. Int J Oncology 14: 745-752, 1999.
28. CihlářT and Chen MS: Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases alpha, beta and gamma. Antivir Chem Chemother 8: 187-195, 1997.
29. Birkuš G, Kramata P, Votruba I, Otová B, Otmar M and Holý A: Nonproteolyzed form of DNA-polymerase e from T-cell spontaneous lymphoma of Sprague-Dawley inbred rat: isolation and characterization. Collect Czech Chem Commun 63: 723-731, 1998.
30. Birkuš G, Votruba I, Holý A and Otová B: 9-[2-(Phosphonomethoxy)ethyl]adenine Diphosphate (PMEApp) as a Substrate toward Replicative DNA Polymerases α, δ, ε and ε*. Biochem Pharmacol 58: 487-492, 1999.
31. Otová B, Francová K. Franěk F, Koutník P. Votruba I, Holý A, Sladká M and Schramlová J: 9-[2-(Phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP) - a Potential Drug against Haematological Malignancies - Induces Apoptosis. Anticancer Res 19: 3173-3182, 1999.
32. Holý A, Gunter J, Dvořáková H, Masjídková M, Andrei G, Snoeck R, Balzarini J and De Clercq E: Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy) ethyl] nucleotidc analogues. 1. Derivatives substituted at the carbon atoms of the base. J Med Chem 42: 2064-2086, 1999.
33. Darzynkiewicz Z, Bruno S, Del Bino G, Gorezyca W, Hotz MA, Lassota P and Traganos F: Features of apoptotic cells measured by flow cytomcery. Cytometry 13: 795-808, 1992.
34. Li X, Darzynkiewicz Z: Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif 28: 572-579, 1994.
35. Li X, Traganos F, Melamed MR and Darzynkiewicz Z: Single step procedure for labelling DNA strand breaks with fluorescein-or DBODIPY-conjugated deoxynucleotides. Detection of apoptosis and BrdUrd incorporation. Cytometry 20: 172-180, 1995.
36. Paydas S: p53 protein expression in leukemias. Acta Oncol 34: 23-26, 1995.
37. Bull EK, Chakrabarty S, Brodsky I and Haines DS: mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells. Oncogene 16: 2249-2257, 1998.
38. Johnston JB, Daeninck P, Verburg L, Lee K, Williams G, Israels LG, Mowat MRA and Begleiter A: P53, MDM-2, BAX and BCL-2 and Drug Resistance in Chronic Lymphocytic Leukemia. Leukemia and Lymphoma 26; 435-449, 1997.
39. Reed J: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
40. Amundson SA, Myers TG and Fornace AJ, Jr: Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17: 3287-3299, 1998.
41. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Crag RW: Participation of p53 protein in cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
42. Corbet SW, Clarke AR, Gledhill S and Wyllie AH: p53-dependent and -independent links between DNA-damage, apoptosis and mutation frequency in ES cells. Oncogene 18: 1537-1544, 1999.
43. Valeriánová M, Bobková K, Holý A, Votruba I and Otová B: Cytostatic and genotoxic effect of 9-(2-phosphonomethoxyethyl)-2,6-diaminopurine and its derivatives. Cells, Editor J. Berger, KOPP, České Budějovice, Czech Republic, p. 139, 1999.
44. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W and Lichter P: 3 gene deletions predicts for a poor survival and non-response to therapy with purine analogs in chronic B-leukemia. Blood 85: 1580-1589, 1995.
45. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Jr and Kohn K: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.
46. Lane DP: Exploiting the p53 pathway for cancer diagnosis and therapy. Brit J Cancer 80: 1-5, 1999.